Merz Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
7
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:1
Phase 2:1
Phase 3:2
+1 more phases
Drug Approvals
1
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (40.0%)Not Applicable
1 (20.0%)Phase 1
1 (20.0%)Phase 2
1 (20.0%)A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Merz Therapeutics GmbH
- Target Recruit Count
- 780
- Registration Number
- NCT07018713
- Locations
- 🇺🇸
Arizona Neuroscience Research, Merz Investigational Site #0010521, Phoenix, Arizona, United States
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Merz Therapeutics GmbH
- Target Recruit Count
- 990
- Registration Number
- NCT07018700
- Locations
- 🇺🇸
Arizona Neuroscience Research, Merz Investigational Site #0010521, Phoenix, Arizona, United States
Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool
Completed
- Conditions
- Post-stroke Spasticity
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Merz Therapeutics GmbH
- Target Recruit Count
- 73
- Registration Number
- NCT06381999
- Locations
- 🇦🇹
Gailtal-Klinik, Hermagor, Austria
A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
Phase 2
Completed
- Conditions
- Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Merz Therapeutics GmbH
- Target Recruit Count
- 123
- Registration Number
- NCT06091020
- Locations
- 🇧🇬
Merz Investigational Site #3590004, Plovdiv, Bulgaria
🇧🇬Merz Investigational Site #3590006, Sofia, Bulgaria
🇧🇬Merz Investigational Site #3590005, Sofia, Bulgaria
Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss
Not Applicable
Completed
- Conditions
- Diffuse Hair Loss in Females
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Merz Therapeutics GmbH
- Target Recruit Count
- 39
- Registration Number
- NCT05943860
- Locations
- 🇩🇪
proDerm, Schenefeld, Germany
- Prev
- 1
- 2
- Next
News
No news found